Common cold can't be termed as sign of coronavirus: AIIMS
Published By : Prameya News Bureau | February 14, 2021 IST
Share
New Delhi, Feb 14: A while ago, a group of general physicians in the UK claimed that common cold symptoms should not be taken for granted, instead treated as a sign of coronavirus. But there is a divergent view, the President of AIIMS, Bhopal and Jammu, Y.K. Gupta told IANS that cough, fever and common cold cannot be 100 per cent termed as signs of coronavirus. Reportedly, 140 east London general practitioners (GPs) and health care professionals had written and signed an open letter to chief medical officer Chris Whitty and Susan Hopkins of Public Health England, claiming that patients usually experience typical symptoms of common cold like sore throat, a runny nose and headaches before testing positive for coronavirus. Gupta, who was former Dean (Academics), and ex-Head, Department of Pharmacology, AIIMS New Delhi, said: "Common cold cannot be 100 per cent sign of coronavirus. Most common cold viral infections are on decline, but that does not mean that people should drop their guard. It is essential to wear mask and maintain social distancing." As the spurt of Covid cases begins to taper, Gupta cautioned though there has been a decline in the Covid cases recently, but this does not mean that danger is over. He stressed the factors contributing towards the decline in cases and deaths could be the ongoing vaccination drive and the intrinsic immunity of people in the country. "A large population has already been infected, which sub clinically may contribute to decline. The pathogenicity of this is decreasing maybe", he said. On the aspect of increasing numbers in western countries and consistent decline in cases in India, Gupta indicated that this is perhaps due to a higher immunity of the Indian population towards the virus than western population, but there is not sufficient data to establish this. People who got vaccinated after contracting Covid-19 have developed some health issues. Does it have a potential to become a lasting health problem? Gupta replied that it may be a residual health problem and not vaccine residual side-effect, in fact after vaccination allergic reaction does not last for more than two days. When queried, has he come across any safety issues associated with Covaxin in any particular age group, especially senior citizen, or people with comorbidities so far, Gupta said nothing so far, because data is not fully available and added that data regarding the Phase 3 trial of Covaxin may be available by March end, which would establish its efficacy. (IANS)
News7 Is Now On WhatsApp Join And Get Latest News Updates Delivered To You Via WhatsApp
You Might Also Like
More From Related News
From pain to comfort: Discover the doctor who cares for your bad back
Boys born to mothers with HIV more vulnerable to death in infancy
World Hemophilia Day: Solidarity for people living with rare genetic disorder
AIIMS Bhubaneswar launches advanced Artificial Urinary Sphincter(AUS) implantation service
Indians up their spending on dieticians by 125 pc in FY24: Report
Zomato introduces 'large order fleet' for gatherings of up to 50 people
Critical patient successfully treated at SUM Phulnakhara campus
Nasal cells shield kids from Covid, Study finds
Scientists decode how exercise can reverse ageing
Remove Bournvita from category of ‘health drinks’: Govt tells e-commerce firms
Menstruation signifies femininity and fertility, not impurity
44% Odisha people never check blood pressure: ICMY study
Say goodbye to dry eyes: Expert tips for relief and comfort
47-year-old Iraqi man wins battle against stage 4 rectal cancer in India
President Murmu calls for improving education system of homoeopathy
Parkinson’s disease: Why it is striking people under 50
Understanding Men Menopause (andropause): Symptoms, Cause & advice
Command Hospital, Pune conducts successful piezoelectric bone conduction hearing implants
Inpatient’s palliative care in Bagchi Karunashraya begins today
SUM Hospital in Berhampur conducts CME on infection control